
EHC: Recognizing Von Willebrand Factor as a Critical Medicine in Bleeding Care
The European Haemophilia Consortium (EHC) recently shared a post on X:
”Von Willebrand Disease affects 1:1000 individuals and, if not recognised, may cause severe bleeding symptoms after trauma or surgery that can be life-threatening. It’s time for health systems to recognise Von Willebrand Factor as a Critical Medicine. European Medicines Agency”
Von Willebrand Disease (VWD), the most common inherited bleeding disorder, affects approximately 1 in 1,000 individuals.
When unrecognized or untreated, it can lead to serious, even life-threatening bleeding, particularly after trauma or surgical procedures.
Despite its prevalence and potential severity, VWD remains underdiagnosed and undertreated in many health systems.
There is an urgent need to designate Von Willebrand Factor (VWF) as a Critical Medicine to ensure timely diagnosis, treatment access, and improved outcomes for patients.
Recognizing VWF’s essential role in bleeding management is a key step toward better care for individuals living with VWD worldwide.
Hemostasis Today, your daily update on the waves in bleeding disorders community.
-
Oct 11, 2025, 09:06Natalia Peres Martinez - Surgical Bleed: Replacing Gut Feeling With Guided Thinking
-
Oct 11, 2025, 09:00Muhammad Ali - Hematology In Pakistan: The Silent Revolution In Diagnosis And A Blueprint For Growth
-
Oct 11, 2025, 08:50Robert Zeiser: New Insights and Timeless Lessons in Transplantation
-
Oct 11, 2025, 08:39Mildred Lundgren: These 5 Proposals Are A Clear Road Map for The Future And We Support Them Wholeheartedly
-
Oct 11, 2025, 08:33RPTH Journal: Does Fasting Affect Anticoagulant Therapy? - The Effects Of Fasting During Ramadan
-
Oct 11, 2025, 18:47Endovascular Today: SYMPHONY-PE Trial and Advances in Pulmonary Embolism Treatment
-
Oct 11, 2025, 08:49Rodrigo Assar: We Are Pushing the Boundaries by Using Computational Approaches
-
Oct 11, 2025, 08:48Deborah Wild: Thrilled to See GeneVentiv Selected for The NIH NHLBI Catalyze Program
-
Oct 11, 2025, 08:34Ivo Francischetti and Colleagues on Glycoprotein VI Contributing to Platelet Activation in HIT
-
Oct 11, 2025, 08:00Michael Hadley: Photon-Counting CT Offers Good Diagnostic Accuracy for Detecting In-Stent Restenosis
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 11, 2025, 08:57Jeff June - Seeing The Invisible: How Spatial Biology Is Opening A New Chapter In Stroke Care
-
Oct 11, 2025, 08:11Khaled Musallam: Honored to Be Featured for The 7th Year in A Row in The World’s Top 2% Most-Cited Scientists
-
Oct 11, 2025, 08:07Britta Diebel: This Has Been An Intense, Good Week, Although IPAW Actually Lasts All Year Long
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?